1. McGorry PD, Killackey E, Yung AR. Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust 2007;187(7 Suppl):S8-S10.
2. Addington J, Heinssen RK, Robinson DG, Schooler NR, Marcy P, Brunette MF, et al. Duration of untreated psychosis in community treatment settings in the United States. Psychiatr Serv 2015;66:753-756.
4. Schimmelmann BG, Huber CG, Lambert M, Cotton S, McGorry PD, Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008;42:982-990.
5. Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am J Psychiatry 2016;173:362-372.
6. Kim SW, Lee BJ, Kim JJ, Yu JC, Lee KY, Won SH, et al. Design and Methodology of the Korean Early Psychosis Cohort Study. Psychiatry Investig 2017;14:93-99.
7. Yoo J, Ahn S, Cho Y, Lee M. A study of duration of untreated psychosis (DUP) for first episode psychosis. Ment Health 2011;2:12-16.
8. Hutton P, Taylor PJ. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol Med 2014;44:449-468.
12. Kim SW, Schafer MR, Klier CM, Berk M, Rice S, Allott K, et al. Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis. Schizophr Res 2014;158:39-44.
13. Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A, et al. Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the PACE 400 study. JAMA Psychiatry 2013;70:793-802.
14. American Psychiatric-Association. Diagnostic and Statistical Manual of Mental Disorder. 5th Ed. Arlington, VA: American Psychiatric Publishing; 2013.
15. Yung AR, Pan Yuen H, Mcgorry PD, Phillips LJ, Kelly D, Dell’olio M, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry 2005;39:964-971.
18. Addington J, Stowkowy J, Weiser M. Screening tools for clinical high risk for psychosis. Early Interv Psychiatry 2015;9:345-356.
19. Chung YC, Kang NI, Im YJ, Kim SW, Cho IH, Lee YM, et al. Validation of the Korean version of the Eppendorf Schizophrenia Inventory as a screening measure to detect adolescents at ultra-high risk for psychosis. Early Interv Psychiatry 2013;7:71-79.
21. Loewy RL, Bearden CE, Johnson JK, Raine A, Cannon TD. The prodromal questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. Schizophr Res 2005;79:117-125.
22. Mass R, Girndt K, Matouschek AK, Peter PM, Plitzko N, Andresen B, et al. Introducing the Eppendorf Schizophrenia Inventory (ESI) as a psychometric method for schizotypy research. Pers Individ Dif 2007;42:525-534.
23. Loewy RL, Therman S, Manninen M, Huttunen MO, Cannon TD. Prodromal psychosis screening in adolescent psychiatry clinics. Early Interv Psychiatry 2012;6:69-75.
24. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33.
25. Han C, Jo SA, Kwak JH, Pae CU, Steffens D, Jo I, et al. Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric study. Compr Psychiatry 2008;49:218-223.
26. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999;282:1737-1744.
27. Kobayashi H, Nemoto T, Koshikawa H, Osono Y, Yamazawa R, Murakami M, et al. A self-reported instrument for prodromal symptoms of psychosis: testing the clinical validity of the PRIME Screen-Revised (PS-R) in a Japanese population. Schizophr Res 2008;106:356-362.
29. Muller M, Vetter S, Buchli-Kammermann J, Stieglitz RD, Stettbacher A, Riecher-Rossler A. The Self-screen-Prodrome as a short screening tool for pre-psychotic states. Schizophr Res 2010;123:217-224.
30. Owoso A, Ndetei DM, Mbwayo AW, Mutiso VN, Khasakhala LI, Mamah D. Validation of a modified version of the PRIME screen for psychosis-risk symptoms in a non-clinical Kenyan youth sample. Compr Psychiatry 2014;55:380-387.
32. O’Toole BI. Screening for low prevalence disorders. Aust N Z J Psychiatry 2000;34(Suppl):S39-S46.
33. Post SG. Preventing schizophrenia and Alzheimer disease: comparative ethics. Schizophr Res 2001;51:103-108.
34. Kim SW, Polari A, Melville F, Moller B, Kim JM, Amminger P, et al. Are current labeling terms suitable for people who are at risk of psychosis? Schizophr Res 2017;188:172-177.
36. Escher S, Romme M, Buiks A, Delespaul P, Van Os J. Independent course of childhood auditory hallucinations: a sequential 3-year follow-up study. Br J Psychiatry Suppl 2002;43:s10-s18.
38. McGorry PD, McFarlane C, Patton GC, Bell R, Hibbert ME, Jackson HJ, et al. The prevalence of prodromal features of schizophrenia in adolescence: a preliminary survey. Acta Psychiatr Scand 1995;92:241-249.
39. Fonseca-Pedrero E, Gooding DC, Ortuno-Sierra J, Paino M. Assessing self-reported clinical high risk symptoms in community-derived adolescents: a psychometric evaluation of the Prodromal Questionnaire-Brief. Compr Psychiatry 2016;66:201-208.
40. McGorry P, Nelson B. Why We need a transdiagnostic staging approach to emerging psychopathology, early diagnosis, and treatment. JAMA Psychiatry 2016;73:191-192.